Article, 2024

Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitis

HEPATOLOGY COMMUNICATIONS, Volume 8, 7, 10.1097/HC9.0000000000000467

Contributors

Thorburn, Douglas (Corresponding author) [1] [2] [3] [4] Leeming, Diana J. [5] Barchuk, William T. [6] Wang, Ya [6] Lu, Xiaomin [6] Malkov, Vladislav A. [6] Ito, Kaori L. [6] Bowlus, Christopher L. [7] [8] Levy, Cynthia [9] Goodman, Zachary [10] Karsdal, Morten A. [5] Muir, Andrew J. [11] Xu, Jun [6]

Affiliations

  1. [1] Royal Free Hosp, Sheila Sherlock Liver Ctr, London NW3 2QG, England
  2. [NORA names: United Kingdom; Europe, Non-EU; OECD];
  3. [2] Royal Free Hosp, Sheila Sherlock Liver Ctr, London NW3 2QG, England
  4. [NORA names: United Kingdom; Europe, Non-EU; OECD];
  5. [3] Royal Free Hosp, Sheila Sherlock Liver Ctr, London NW3 2QG, England
  6. [NORA names: United Kingdom; Europe, Non-EU; OECD];
  7. [4] Royal Free Hosp, Sheila Sherlock Liver Ctr, London NW3 2QG, England
  8. [NORA names: United Kingdom; Europe, Non-EU; OECD];
  9. [5] Nordic BioSci AS, Herlev, Denmark
  10. [NORA names: Denmark; Europe, EU; Nordic; OECD];

Abstract

Abstract not displayed. As this article is not marked as Open Access, it is unclear if we are allowed to show the abstract. Please use the link in the sidebar to view the data provider version of the article including abstract.

Data Provider: Clarivate